Fallopian tube neoplasm

This early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…

This large phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) and the targeted therapy olaparib (Lynparza) to standard chemotherapy helps women with advanced ovarian cancer that does not have a BRCA mutation. Over 1,300 participants received eithe…

This study looked at whether giving heated chemotherapy directly into the abdomen during a second-look surgery is possible for people with ovarian, fallopian tube, or peritoneal cancer. Ten participants who had already received standard treatment were enrolled. The goal was to se…

This phase II trial tested two immunotherapy drugs, durvalumab and tremelimumab, in 100 women with ovarian, fallopian tube, or peritoneal cancer that had come back or stopped responding to platinum-based chemotherapy. The study compared giving the drugs together versus one after …

This early-stage trial tested two drugs—niraparib and copanlisib—in 31 people with recurrent endometrial, ovarian, peritoneal, or fallopian tube cancer. The goal was to find the safest dose and see how well patients tolerated the combination. Both drugs work by blocking enzymes t…

This phase II trial investigates whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin and paclitaxel) improves outcomes for people with advanced stage III-IV ovarian, fallopian tube, or primary peritoneal cancer. The study aims to s…

This phase II trial tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy drug carboplatin can prevent ovarian, fallopian tube, or primary peritoneal cancer from progressing after a blood test shows it may have returned. The study includes …

This completed phase 2 trial tested whether the drug cediranib, given with chemotherapy, is safe for women with advanced ovarian cancer who are at risk of bowel obstruction. 30 participants received the combination. The study focused on whether the treatment caused serious bowel …

This study tested a new immunotherapy called Olvi-Vec, which uses a modified virus to attack cancer cells, in 46 patients with ovarian cancer that had come back or stopped responding to standard treatments. The goal was to see if the treatment was safe and could slow tumor growth…

This phase 2 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) could help keep cancer from growing in people with platinum-resistant ovarian, fallopian tube, or peritoneal cancer. After initial chemotherapy with paclitaxel, 20 participants received pembrolizuma…

This study tested a new drug, farletuzumab ecteribulin, which targets a protein found on many ovarian cancer cells. It was compared to standard chemotherapy in 106 women whose ovarian cancer had stopped responding to platinum-based treatments. The goal was to see if the new drug …

This phase II trial tested whether adding metformin, a common diabetes drug, to standard chemotherapy could help control advanced ovarian, fallopian tube, or primary peritoneal cancer. 111 participants received either metformin or a placebo alongside chemotherapy, followed by mai…

This study tests a new drug called ZN-c3 (azenosertib), either alone or combined with niraparib, in 117 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to find safe doses and see if the drugs can shrink tumors. It is an early-stage trial, s…

This phase 2 trial tested a drug called mirvetuximab soravtansine in 79 people with recurrent platinum-sensitive ovarian, peritoneal, or fallopian tube cancers that have high levels of a protein called folate receptor-alpha. The drug is given by IV every three weeks. The main goa…

This study tested a new drug called RC88 in 43 women with ovarian, fallopian tube, or peritoneal cancer that stopped responding to platinum chemotherapy. The goal was to see if RC88 alone could shrink tumors and how safe it was. Participants had already tried at least three other…

This early-phase study tested a new drug called SL-172154 combined with either of two standard chemotherapies in 86 people with ovarian cancer that had stopped responding to platinum-based treatment. The main goals were to check safety and find the best dose. Researchers also loo…

This early-stage trial tested an experimental drug called Z-Endoxifen in 40 adults with hormone receptor-positive cancers (like breast, ovarian, or desmoid tumors) that had stopped responding to standard treatments. Z-Endoxifen is a direct form of tamoxifen's active ingredient, b…

This Phase 1 trial tested a personalized immunotherapy called TG4050 in 64 women with advanced ovarian, fallopian tube, or peritoneal cancer who had completed standard chemotherapy and were in complete remission. The treatment is made from each patient's unique tumor mutations an…

This early-phase trial tested a personalized vaccine made from a patient's own immune cells to see if it is safe for people with advanced ovarian, fallopian tube, or peritoneal cancer. Nineteen participants who had already undergone surgery and chemotherapy received the vaccine. …

This study tested a new drug called relacorilant combined with chemotherapy (nab-paclitaxel) in 178 women with ovarian, fallopian tube, or peritoneal cancer that came back and no longer responds to platinum-based treatments. The goal was to see if the combination helps keep the c…

This study tested whether giving heated chemotherapy directly into the abdomen during surgery can improve quality of life for people with advanced ovarian, fallopian tube, or peritoneal cancer. Fifty participants received the treatment after standard chemotherapy. Researchers mea…

This study tested whether adding the drug aprepitant to standard anti-nausea medicine helps women with gynecologic cancers (like ovarian or cervical cancer) who are getting chemotherapy. 143 women took part. The goal was to see if the extra drug could better prevent nausea and vo…

This early-phase study tested a precise type of radiation called stereotactic body radiation therapy (SBRT) in 15 women whose ovarian or uterine cancer had come back in a limited area. The main goal was to find the safest dose and check for side effects. Researchers also looked a…

This study looks at proteins in the blood of women with ovarian, peritoneal, or fallopian tube cancer who are in remission. The goal is to find a protein pattern, or 'fingerprint,' that signals when the cancer might come back. Researchers followed 119 women with stage III or IV c…

This study looked at 1,500 women with advanced ovarian, peritoneal, or fallopian tube cancer to see how genetic changes in their tumors relate to how the disease progresses. Researchers collected tumor samples and medical data to find links between DNA abnormalities and outcomes …

This study looked back at 388 women with advanced ovarian, fallopian tube, or peritoneal cancer who were taking the drug niraparib as maintenance therapy. Researchers wanted to see how often serious side effects happened and how patients used the drug in real-life UK clinics. No …

This study tested whether it is practical to routinely check ovarian cancer tumors for BRCA gene mutations in the clinic. Researchers enrolled 200 patients with high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer. They used blood and tumor samp…

This study reviewed medical records of 51 women with ovarian, fallopian tube, or peritoneal cancer who received the drug rucaparib in real-world clinics, not just in strict trials. Researchers looked at patient history, side effects, dosing, and how long the drug kept cancer from…

This study tested a digital chatbot (called CATALYST) to help cancer survivors learn about genetic testing for inherited cancer risk. Fifty adults who had certain cancers (like breast, ovarian, or prostate) used the chatbot or received usual care. The goal was to see if the chatb…

This study tested whether saliva samples can be used to remotely monitor cytomegalovirus (CMV) infection in people receiving treatment for ovarian cancer. Researchers compared saliva and blood samples from 49 participants, collected either at the clinic or at home. The goal was t…

This study followed 102 women with ovarian, fallopian tube, or endometrial cancer through six cycles of standard chemotherapy (carboplatin and paclitaxel). Researchers measured taste changes, muscle loss, and nutritional decline at the start, halfway, and end of treatment. The go…